{
    "clinical_study": {
        "@rank": "60456", 
        "arm_group": [
            {
                "arm_group_label": "TELMINUVO Tab. (80/2.5mg, 80/5mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "S-Amlodipine 2.5, 5mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of present study is to evaluate the efficacy and safety of two dose combination of\n      Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg\n      and 5mg) in patients with Stage 2 hypertension."
        }, 
        "brief_title": "Efficacy and Safety of TELMINUVO to Stage 2 Hypertension", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "-  In patients with Stage 2 hypertension to determine the efficacy and safety of\n           Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) or S-Amlodipine monotherapy (2.5mg and\n           5mg) during 8 weeks.\n\n        -  This study is consist of placebo run-in period(2 weeks_single blind) and treatment\n           period(8 weeks_double blind)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18 years or older\n\n          -  at the screening visit\n\n               -  antihypertensive drugs not taking: 160mmHg \u2264 sitSBP < 200mmHg\n\n               -  antihypertensive drugs taking: 140mmHg \u2264 sitSBP < 180mmHg\n\n          -  at the randomization visit(160mmHg \u2264 sitSBP < 200mmHg)\n\n          -  willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  mean sitting DBP \u2265 120mmHg or mean sitting SBP \u2265 200mmHg at the screening visit and\n             randomization visit\n\n          -  for the past four weeks based on beginning of administration, patients took over four\n             antihypertensive drugs\n\n          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary\n             hyperaldosteronism, renal artery stenosis, pheochromocytoma)\n\n          -  has severe heart disease(Heart failure NYHA functional class 3, 4), ischaemic heart\n             diseases status need to treatment, myocardiopathy, Valve disease, arrhythmia and so\n             on and operated Coronary angioplasty\n\n          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6\n             months\n\n          -  Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as\n             defined by fasting glucosylated hemoglobin(HbA1c) > 8%)\n\n          -  known severe or malignant retinopathy\n\n          -  defined by the following laboratory parameters:\n\n               -  hepatic dysfunction(AST/ALT > UNL X 3)\n\n               -  renal dysfunction(serum creatinine > UNL X 1.5)\n\n               -  hypopotassemia(K < 3.0mmol/L) or hyperpotassemia (K>5.5 mmol/L)\n\n          -  acute or chronic inflammatory status need to treatment\n\n          -  need to additional antihypertensive drugs during the study\n\n          -  need to concomitant medications known to affect blood pressure during the study\n\n          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers\n\n          -  known hypersensitivity related to either study drug\n\n          -  history of drug or alcohol dependency within 6 months\n\n          -  any surgical or medical condition which might significantly alter the absorption,\n             distribution, metabolism, or excretion of investigational products(ex.\n             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,\n             active inflammatory bowel syndrome within 12 months prior to screening, gastric\n             ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic\n             function such as pancreatitis, obstructions of the urinary tract or difficulty in\n             voiding)\n\n          -  administration of other study drugs within 4weeks prior to screening\n\n          -  premenopausal women(last menstruation > 1year) not using adequate contraception,\n             pregnant or breast-feeding\n\n          -  history of malignancy including leukemia and lymphoma within the past 5 years\n\n          -  in investigator's judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983735", 
            "org_study_id": "130HT13015"
        }, 
        "intervention": [
            {
                "arm_group_label": "TELMINUVO Tab. (80/2.5mg, 80/5mg)", 
                "description": "Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.\nWith the others investigation product placebo 1 tab QD 2 weeks.", 
                "intervention_name": "TELMINUVO Tab. (80/2.5mg)", 
                "intervention_type": "Drug", 
                "other_name": "TELMINUVO Tab."
            }, 
            {
                "arm_group_label": "TELMINUVO Tab. (80/2.5mg, 80/5mg)", 
                "description": "Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.\nWith the others investigation product placebo 1 tab QD 6 weeks.", 
                "intervention_name": "TELMINUVO Tab. (80/5mg)", 
                "intervention_type": "Drug", 
                "other_name": "TELMINUVO Tab."
            }, 
            {
                "arm_group_label": "S-Amlodipine 2.5, 5mg", 
                "description": "S-amlodipine 2.5mg QD 2 weeks\nWith the others investigation product placebo 1 tab QD 2 weeks.", 
                "intervention_name": "S-amlodipine 2.5mg", 
                "intervention_type": "Drug", 
                "other_name": "Anydipine S"
            }, 
            {
                "arm_group_label": "S-Amlodipine 2.5, 5mg", 
                "description": "S-amlodipine 5mg QD 6weeks\nWith the others investigation product placebo 1 tab QD 6 weeks.", 
                "intervention_name": "S-amlodipine 5mg", 
                "intervention_type": "Drug", 
                "other_name": "Anydipine S"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Telmisartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TELMINUVO Tab.", 
            "CKD-828", 
            "Hypertension", 
            "Stage 2 Hypertension", 
            "S-Amlodipine", 
            "Telmisartan"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "email": "younhj@catholic.ac.kr", 
                "last_name": "Ho-Joong Yoon, Ph.D", 
                "phone": "82-2-2258-6029"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "The catholic university of Korea Seoul St. Mary's hospital"
            }, 
            "investigator": {
                "last_name": "Ho-Joong Yoon, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension", 
        "overall_contact": {
            "email": "younhj@catholic.ac.kr", 
            "last_name": "Ho-Joong Yoon, Ph.D", 
            "phone": "82-2-2258-6029"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Sitting Systolic Blood Pressure (MSSBP)", 
            "safety_issue": "No", 
            "time_frame": "After 8 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983735"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Sitting Systolic Blood Pressure (MSSBP)", 
                "safety_issue": "No", 
                "time_frame": "After 2 weeks and 4 weeks of treatment"
            }, 
            {
                "measure": "Mean Sitting Diastolic Blood Pressure (MSDBP)", 
                "safety_issue": "No", 
                "time_frame": "After 2weeks, 4weeks and 8 weeks of treatment"
            }, 
            {
                "description": "Sitting SBP<140mmHg, Sitting DBP<90mmHg", 
                "measure": "Control Rate", 
                "safety_issue": "No", 
                "time_frame": "After 8 weeks of treatment"
            }, 
            {
                "description": "Reduction of Sitting SBP\u226520mmHg, Sitting DBP \u226510mmHg", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "After 8 weeks of treatment"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}